Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump Signs Redundant Executive Order Calling For Coverage Of Preexisting Conditions

The EO also describes actions the administration has been taking to end “surprise billing”

Executive Summary

President Trump is flayed by Democrats for using an executive order to grab credit for a preexisting conditions coverage mandate that’s already contained in the Affordable Care Act, signed by President Obama.

You may also be interested in...



Legal Experts Predict How US Supreme Court Shake-Up Will Impact Medtech

If President Donald Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsburg, Affordable Care Act coverage could disappear. Two legal experts weigh in on this and other legal issues that could touch the medical device industry.

CMS Final Kidney Disease Treatment Model To Encourage More Home Dialysis

The US Medicare agency introduced a new end-stage renal disease treatment model on Friday to incentivize use of home dialysis.

Congress Tackles Overpriced ‘Surprise’ Medical Bills, Taking Several Different Tacks

A trio of legislative proposals to lower high-cost “surprise” medical bills that limit what physicians and hospitals, labs, and imaging facilities can charge patients, emerged this winter from three different US congressional committees with health care jurisdiction. Check out our detailed chart that sorts out some of the provisions of the bills of interest to device and diagnostics firms.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT142801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel